D
Drug Farm accelerates pharmaceutical development through advanced drug discovery platforms for global biotech and pharma companies.
$55MSeries D
Investor undisclosed
A $55M Series D for a Chinese drug discovery platform signals that computational biotech is maturing past hype—this isn't seed-stage AI-for-drugs anymore, it's capital flowing to companies with actual pharma customer traction. If you're building B2B tools for regulated industries (biotech, medtech, materials), this validates that enterprises will pay for platforms that compress timelines, even if adoption cycles are long.